The Association of Community Cancer Centers launched the ACCC Community Oncology Research Institute, which builds on the organization's mission to close the gap in cancer research through optimal community oncology partnerships.
The Association of Community Cancer Centers (ACCC) recently announced the launch of the ACCC Community Oncology Research Institute (ACORI), building on its existing mission to close the gap in cancer research through optimal community oncology partnerships.
ACORI works to establish clinical trials as a standard of care in treatment plans and to help achieve equitable cancer care delivery for all patients, according to a release.
The Institute evolved from ACCC's year-long examination of equity and access to clinical trials in the community under the direction of its Immediate Past President Randall A. Oyer, MD., who will lead the team of recognized multidisciplinary cancer team professionals.
"Communities belong in cancer research and cancer research belongs in the community," said Oyer. "Connecting community cancer centers through partnerships will help overcome persistent barriers that exist to conducting research in the community. Regardless of a cancer center's size, location, or resources, community oncology research cannot flourish on its own. Partnerships are needed between academic and research centers of excellence, other community integrated networks, and others working in all aspects of cancer research, most importantly, patients and community organizations who can bi-directionally inform research design and conduct. By sharing resources, we can help make any community oncology program research-ready."
The ACCC Community Oncology Research Institute is focused on three primary domains:
As its foundational project, ACCC has collaborated with the American Society of Clinical Oncology (ASCO) to increase cancer clinical trial participation among patients from underrepresented racial and ethnic groups. The two organizations are currently recruiting 40 oncology research programs to be part of a pilot testing a site assessment tool and/or an implicit bias training program. ACCC and ASCO are seeking a mix of small and large oncology programs from diverse regions around the country, and participating programs will receive a stipend. Interested programs may complete an application by June 11, 2021.
Reducing Low-Value Care in Oncology
November 10th 2023The Choosing Wisely campaign has helped with overscreening and overtreatment. Some experts say better management of end-of-life care and value-based payment would also help steer oncology away from care with poor cost-benefit ratios.
Read More
Using the 'Pathway' Approach to Shorten the Time Between Cancer Diagnosis and Treatment
November 16th 2022In this episode of Tuning In to the C-Suite, Briana Contreras, editor with Managed Healthcare Executive spoke with Dr. Yuri Fesko, oncologist and vice president of Medical Affairs at Quest Diagnostics. In the conversation, Dr. Fesko addressed the ongoing issue of long gaps of times between receiving a diagnosis for a type of cancer and finally getting the treatment for it. Dr. Fesko shared the benefits a number of sectors receive when treating patients sooner and the steps to get there.
Listen
Takeda to Withdraw Oncology Drug Exkivity from U.S. Market
October 2nd 2023In a confirmatory trial, Exkivity did not meet the primary endpoint in treating patients with non-small cell lung cancer with EGFR exon 20 mutations. It will remain available while Takeda works with the FDA on withdrawal timing.
Read More
MHE Associate Editor, Briana Contreras, spoke with CEO of Inteliquet, a cancer solutions provider that strives to match patients to clinical trials accurately and promptly in healthcare, Marie Lamont. In this episode Marie discusses the challenges that have affected clinical trials and cancer screenings and how to get trials back on track through technology to avoid the wave of undiagnosed patients post-COVID. She also shared how broadening them through diversity can improve trials.
Listen